Abstract

BackgroundPoor adherence to inhaled corticosteroid medications for children with high-risk asthma is both well documented and poorly understood. It has a disproportionate prevalence and impact on children of minority demographics in urban settings. Financial incentives have been shown to be a compelling method to engage those in a high-risk asthma population, but whether adherence can be maintained by offering financial incentives and how these incentives can be used to sustain high adherence are unknown.ObjectiveThe aim of this study is to determine the marginal effects of a financial incentive–based intervention on inhaled corticosteroid adherence, health care system use, and costs.MethodsParticipants include children aged 5 to 12 years who have had either at least two hospitalizations or one hospitalization and one emergency department visit for asthma in the year prior to their enrollment (and their caregivers). Participants are given an electronic inhaler sensor in order to track their medication use over a period of 7 months. After a 1-month period of observation, participants are randomized to 1 of 3 arms for a 3-month period. Participants in arm 1 receive daily text message reminders, feedback, and gain–framed, nominal financial incentives; participants in arm 2 receive daily text message reminders and feedback only, and participants in arm 3 receive no reminders, feedback, or incentives. All participants are subsequently observed for an additional 3-month period with no reminders, feedback, or incentives to assess whether any sustained effects are apparent.ResultsStudy enrollment began in September 2019 with a target sample size of N=125 children. As of June 2020, 61 children have been enrolled. Data collection is estimated to be completed in June 2022, and analyses will be completed by June 2023.ConclusionsThis study will provide data that will help to determine whether a financial incentive–based mobile health intervention for promoting inhaled corticosteroid use can be effective in patients with high-risk asthma over longer periods.Trial RegistrationClinicaltrial.gov NCT03907410; https://clinicaltrials.gov/ct2/show/NCT03907410International Registered Report Identifier (IRRID)DERR1-10.2196/16711

Highlights

  • Poor adherence to asthma control medication is well documented yet poorly understood

  • The proportion of participants who were approached for consent and enrolled was high (69%), and mean adherence during the intervention month (80%) was robust; adherence dropped to 33% after incentives, reminders, and feedback ceased [15]. These findings revealed that financial incentives were a compelling method to engage this high-risk asthma population in regular inhaled corticosteroid use; whether adherence can be maintained and how it can be sustained in pediatric populations is still unknown

  • The primary objective of this study is to determine the marginal effects of a financial incentive–based intervention for inhaled corticosteroid adherence on monthly adherence in children of minority demographics living in urban settings

Read more

Summary

Introduction

Poor adherence to asthma control medication is well documented yet poorly understood. Few studies have attempted to leverage mobile health technology (mHealth) and incentive design to improve medication adherence in children with high-risk asthma. Poor adherence to inhaled corticosteroid medications for children with high-risk asthma is both well documented and poorly understood. It has a disproportionate prevalence and impact on children of minority demographics in urban settings. Objective: The aim of this study is to determine the marginal effects of a financial incentive–based intervention on inhaled corticosteroid adherence, health care system use, and costs. Conclusions: This study will provide data that will help to determine whether a financial incentive–based mobile health intervention for promoting inhaled corticosteroid use can be effective in patients with high-risk asthma over longer periods. Trial Registration: Clinicaltrial.gov NCT03907410; https://clinicaltrials.gov/ct2/show/NCT03907410 International Registered Report Identifier (IRRID): DERR1-10.2196/16711

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call